Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer
Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · Jul 24, 2009
Trial Information
Current as of July 24, 2025
Unknown status
Keywords
ClinConnect Summary
OBJECTIVES:
* To test the feasibility of delivering hypofractionated intensity-modulated radiotherapy to the prostate and pelvic nodes of patients with prostate cancer.
* To determine the optimal dose level of this treatment regimen to be used in future studies.
OUTLINE: Patients are stratified according to small bowel total volume (low small bowel volume \< 450 cc vs high small bowel volume ≥ 450 cc).
Patients undergo hypofractionated intensity-modulated radiotherapy to the prostate and pelvis for 4 weeks in the absence of disease progression or unacceptable toxicity.
After completion ...
Gender
MALE
Eligibility criteria
- DISEASE CHARACTERISTICS:
- * Diagnosis of prostate cancer meeting 1 of the following criteria:
- • Stage T3b/T4 disease or radiological or pathological pelvic nodal metastases
- • Localized disease (stage pT2-T4) with \> 30% estimated risk of pelvic nodal metastases
- • High-risk (Gleason score ≥ 8 or ≥ 2 risk factors) or very high-risk disease according to the National Collaborative Cancer Network (NCCN)
- • Has undergone prostatectomy AND has stage T2-T3a, N0 disease with extensive high-risk disease (Gleason score ≥ 8) or seminal vesicle or lymph node involvement
- • Candidate for radical radiotherapy
- PATIENT CHARACTERISTICS:
- • No inflammatory bowel disease or other small bowel disease
- PRIOR CONCURRENT THERAPY:
- • No prior pelvic radiotherapy or surgery (excluding prostatectomy)
About Royal Marsden Nhs Foundation Trust
The Royal Marsden NHS Foundation Trust is a leading cancer treatment and research institution in the UK, renowned for its commitment to advancing oncology through innovative clinical trials and cutting-edge therapies. With a multidisciplinary team of experts, the Trust integrates patient care with groundbreaking research, fostering a collaborative environment to improve outcomes for cancer patients. As a pioneer in the field, the Royal Marsden actively contributes to the development of new treatment protocols and plays a critical role in translating scientific discoveries into clinical practice, ensuring that patients have access to the latest advancements in cancer care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sutton, England, United Kingdom
Sutton, England, United Kingdom
London, England, United Kingdom
Patients applied
Trial Officials
David P. Dearnaley, MD, FRCP, FRCR
Principal Investigator
Royal Marsden NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials